Evidence map›Paper›PMID 26811165›Full record

Trial reportJournal of the American Heart Association2016

Comprehensive Assessment of Coronary Plaque Progression With Advanced Intravascular Imaging, Physiological Measures, and Wall Shear Stress: A Pilot Double-Blinded Randomized Controlled Clinical Trial of Nebivolol Versus Atenolol in Nonobstructive Coronary Artery Disease.

Olivia Y Hung, David Molony, Michel T Corban, Emad Rasoul-Arzrumly, Charles Maynard, Parham Eshtehardi, Saurabh Dhawan, Lucas H Timmins, Marina Piccinelli, Sung Gyun Ahn and 5 more

Registry-linked trialOpen access · goldAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Heart Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01230892 (The Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Artery Plaques in Patients With Moderate Coronary Artery Disease), which is not on this map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01230892 phase4completednot on this map

The Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Artery Plaques in Patients With Moderate Coronary Artery Disease

TypeinterventionalSponsorEmory UniversityRan2010 to 2013Enrolled29ConditionsAtherosclerosis, Endothelial FunctionArmsNebivolol, Atenolol
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Women's health: making cardiovascular disease real.Current opinion in cardiology · 2018
    Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Olivia Y HungDivision of Cardiology, Department of Medicine, Andreas Gruentzig Cardiovascular Center, Emory University School of Medicine, Atlanta, GA (O.Y.H., M.T.C., E.R.A., P.E., S.D., L.H.T., S.G.A., B.D.G., M.C.M.D., A.A.Q., H.S.).
David MolonyWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA (D.M., L.H.T., D.P.G.).
Michel T CorbanDivision of Cardiology, Department of Medicine, Andreas Gruentzig Cardiovascular Center, Emory University School of Medicine, Atlanta, GA (O.Y.H., M.T.C., E.R.A., P.E., S.D., L.H.T., S.G.A., B.D.G., M.C.M.D., A.A.Q., H.S.).
Emad Rasoul-ArzrumlyDivision of Cardiology, Department of Medicine, Andreas Gruentzig Cardiovascular Center, Emory University School of Medicine, Atlanta, GA (O.Y.H., M.T.C., E.R.A., P.E., S.D., L.H.T., S.G.A., B.D.G., M.C.M.D., A.A.Q., H.S.).
Charles MaynardDepartment of Health Services, University of Washington, Seattle, WA (C.M.).
Parham EshtehardiDivision of Cardiology, Department of Medicine, Andreas Gruentzig Cardiovascular Center, Emory University School of Medicine, Atlanta, GA (O.Y.H., M.T.C., E.R.A., P.E., S.D., L.H.T., S.G.A., B.D.G., M.C.M.D., A.A.Q., H.S.).
Saurabh DhawanDivision of Cardiology, Department of Medicine, Andreas Gruentzig Cardiovascular Center, Emory University School of Medicine, Atlanta, GA (O.Y.H., M.T.C., E.R.A., P.E., S.D., L.H.T., S.G.A., B.D.G., M.C.M.D., A.A.Q., H.S.).
Lucas H TimminsDivision of Cardiology, Department of Medicine, Andreas Gruentzig Cardiovascular Center, Emory University School of Medicine, Atlanta, GA (O.Y.H., M.T.C., E.R.A., P.E., S.D., L.H.T., S.G.A., B.D.G., M.C.M.D., A.A.Q., H.S.) Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA (D.M., L.H.T., D.P.G.).
Marina PiccinelliDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, GA (M.P.).
Sung Gyun AhnDivision of Cardiology, Department of Medicine, Andreas Gruentzig Cardiovascular Center, Emory University School of Medicine, Atlanta, GA (O.Y.H., M.T.C., E.R.A., P.E., S.D., L.H.T., S.G.A., B.D.G., M.C.M.D., A.A.Q., H.S.) Division of Cardiology, Department of Internal Medicine, Yonsei UniversityWonju College of Medicine, Wonju, Republic of Korea (S.G.A.).
Bill D GogasDivision of Cardiology, Department of Medicine, Andreas Gruentzig Cardiovascular Center, Emory University School of Medicine, Atlanta, GA (O.Y.H., M.T.C., E.R.A., P.E., S.D., L.H.T., S.G.A., B.D.G., M.C.M.D., A.A.Q., H.S.).
Michael C McDanielDivision of Cardiology, Department of Medicine, Andreas Gruentzig Cardiovascular Center, Emory University School of Medicine, Atlanta, GA (O.Y.H., M.T.C., E.R.A., P.E., S.D., L.H.T., S.G.A., B.D.G., M.C.M.D., A.A.Q., H.S.).
Arshed A QuyyumiDivision of Cardiology, Department of Medicine, Andreas Gruentzig Cardiovascular Center, Emory University School of Medicine, Atlanta, GA (O.Y.H., M.T.C., E.R.A., P.E., S.D., L.H.T., S.G.A., B.D.G., M.C.M.D., A.A.Q., H.S.).
Don P GiddensWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA (D.M., L.H.T., D.P.G.).
Habib SamadyDivision of Cardiology, Department of Medicine, Andreas Gruentzig Cardiovascular Center, Emory University School of Medicine, Atlanta, GA (O.Y.H., M.T.C., E.R.A., P.E., S.D., L.H.T., S.G.A., B.D.G., M.C.M.D., A.A.Q., H.S.).
Emory University · USThe Wallace H. Coulter Department of Biomedical Engineering · USGeorgia Institute of Technology · USUniversity of Washington · US

Funding

Research Trainng in Academic CardiologyT32HL007745 · NHLBI · EMORY UNIVERSITY · PI TAYLOR, WILLIAM ROBERT · 1994 to 2023
$10.6M
NHLBI NIH HHS 5T32HL007745NHLBI NIH HHS T32 HL007745
6 · The paper itself

Abstract

backgroundWe hypothesized that nebivolol, a β-blocker with nitric oxide-mediated activity, compared with atenolol, a β-blocker without such activity, would decrease oxidative stress and improve the effects of endothelial dysfunction and wall shear stress (WSS), thereby reducing atherosclerosis progression and vulnerability in patients with nonobstructive coronary artery disease. METHODS AND

resultsIn this pilot double-blinded randomized controlled trial, 24 patients treated for 1 year with nebivolol 10 mg versus atenolol 100 mg plus standard medical therapy underwent baseline and follow-up coronary angiography with assessments of inflammatory and oxidative stress biomarkers, microvascular function, endothelial function, and virtual histology intravascular ultrasound. WSS was calculated from computational fluid dynamics. Virtual histology intravascular ultrasound segments were assessed for vessel volumetrics and remodeling. There was a trend toward more low-WSS segments in the nebivolol cohort (P=0.06). Low-WSS regions were associated with greater plaque progression (P<0.0001) and constrictive remodeling (P=0.04); conversely, high-WSS segments demonstrated plaque regression and excessive expansive remodeling. Nebivolol patients had decreased lumen and vessel areas along with increased plaque area, resulting in more constrictive remodeling (P=0.002). There were no significant differences in biomarker levels, microvascular function, endothelial function, or number of thin-capped fibroatheromas per vessel. Importantly, after adjusting for β-blocker, low-WSS segments remained significantly associated with lumen loss and plaque progression.

conclusionNebivolol, compared with atenolol, was associated with greater plaque progression and constrictive remodeling, likely driven by more low-WSS segments in the nebivolol arm. Both β-blockers had similar effects on oxidative stress, microvascular function, and endothelial function. CLINICAL

trial registrationURL: https://clinicaltrials.gov/. Unique identifier: NCT01230892.

Indexed as

Diagnostic ImagingPlaque, AtheroscleroticAdrenergic beta-3 Receptor AgonistsAdrenergic beta-AntagonistsAdultAtenololBiomarkersCoronary AngiographyCoronary Artery DiseaseCoronary CirculationCoronary VesselsDouble-Blind MethodEchocardiography, DopplerFemaleGeorgiaHemodynamicsAdrenergic beta-3 Receptor AgonistsAdrenergic beta-AntagonistsAtenololBiomarkersNebivololcoronary flowcoronary microvascular functionendothelial functionintravascular ultrasoundwall shear stress

Identifiers

PMID26811165
PMCPMC4859395
OpenAlexW2255249516

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.